Open EyeBeta

A public record of U.S. government and large ownership

Brand

CAPLYTA

CAPLYTA is a treatment for schizophrenia and for depressive episodes associated with bipolar disorder and major depressive disorder. Johnson & Johnson's fiscal 2025 Form 10-K says it was acquired with Intra-Cellular Therapies on April 2, 2025.

PharmaceuticalsHealthcare

Documented stakes

  • Johnson & JohnsonControlling stakeHigh confidence

    Listed as a key product in the Innovative Medicine segment of Johnson & Johnson's Form 10-K for the fiscal year ended December 28, 2025. The filing says many of these medicines were developed in collaboration with partners or licensed from other companies. The filing says CAPLYTA was acquired with Intra-Cellular Therapies on April 2, 2025.

    As of Apr 2, 2025. Last checked Sep 22, 2026.